*Refresh the page if the below document does not appear.
As part of its attempts to increase affordability, Dr. Reddy’s Laboratories wants to guarantee that at least 25% of its product releases are first-to-market by 2027, according to its Co-Chairman and Managing Director.
Gland Pharma plans to strengthen product mix at Cenexi, but the high cost base of industrial facilities in wealthy countries makes increasing profitability challenging. The firm is buying the Cenexi group, a European company with notably lower profit margins than Gland Pharma.
The National Pharmaceutical Pricing Authority (NPPA) has announced the second batch of proposed ceiling prices for 43 formulations. As per the draft calculation sheet, the prices of two formulations have been cut by more than half, and the prices of three others have been decreased by 40-50 percent.
Roivant Sciences and Pfizer established a unit to create RVT-3101, a medication that both companies hope to use to treat inflammatory bowel disease. A mid-stage trial is now evaluating the drug’s efficacy as a treatment for ulcerative colitis.
REBYOTA, an unique first-in-class microbiotabased live biotherapeutic indicated for the prevention of recurrence of Clostridioides difficile infection (CDI) in patients 18 years of age and older, has been approved by the US Food and Drug Administration (USFDA).
India wants to strengthen its connections with Africa. The healthcare sector has been suggested as one area where trade across the continents can develop. Young African doctors are thus encouraged to complete their education in India, and in the meantime, Indian healthcare companies are spreading throughout Africa.
New critical data could help GSK expand into a broader endometrial cancer population as it strives to match its PD-1 blocking antibody Jemperli to Merck’s superstar Keytruda. GSK intends to file regulatory submissions based on the trial results in the first half of 2023.
If you don’t already have an account click the button below to create your account.Create New Account
Please update your profile to keep using the website